Enkel behandling mot MS kan bota sjukdomen

[bollio]

Italian Dr. Paolo Zamboni has put forward the idea that many types of MS are actually caused by a blockage of the pathways that remove excess iron from the brain - and by simply clearing out a couple of major veins to reopen the blood flow, the root cause of the disease can be eliminated.
Dr. Zamboni's revelations came as part of a very personal mission - to cure his wife as she began a downward spiral after diagnosis. Reading everything he could on the subject, Dr. Zamboni found a number of century-old sources citing excess iron as a possible cause of MS. It happened to dovetail with some research he had been doing previously on how a buildup of iron can damage blood vessels in the legs - could it be that a buildup of iron was somehow damaging blood vessels in the brain?

He immediately took to the ultrasound machine to see if the idea had any merit - and made a staggering discovery. More than 90% of people with MS have some sort of malformation or blockage in the veins that drain blood from the brain. Including, as it turned out, his wife.

He formed a hypothesis on how this could lead to MS: iron builds up in the brain, blocking and damaging these crucial blood vessels. As the vessels rupture, they allow both the iron itself, and immune cells from the bloodstream, to cross the blood-brain barrier into the cerebro-spinal fluid. Once the immune cells have direct access to the immune system, they begin to attack the myelin sheathing of the cerebral nerves - Multiple Sclerosis develops.

He named the problem Chronic Cerebro-Spinal Venous Insufficiency, or CCSVI.

Zamboni immediately scheduled his wife for a simple operation to unblock the veins - a catheter was threaded up through blood vessels in the groin area, all the way up to the effected area, and then a small balloon was inflated to clear out the blockage. It's a standard and relatively risk-free operation - and the results were immediate. In the three years since the surgery, Dr. Zamboni's wife has not had an attack.

Widening out his study, Dr. Zamboni then tried the same operation on a group of 65 MS-sufferers, identifying blood drainage blockages in the brain and unblocking them - and more than 73% of the patients are completely free of the symptoms of MS, two years after the operation.

http://www.gizmag.com/ccsvi-multiple...zamboni/13447/

[Kwon]

Släkt med Bolio?

[mikaelj]

Tufft! Jag har en bekant med MS. Om det visar sig fungera för fler skulle det här vara fantastiskt.

[Nitrometan]

Heter han Zamboni? Som ismaskinen?

An ice resurfacer is a truck-like vehicle or smaller device used to clean and smooth the surface of an ice rink. The first ice resurfacer was developed by Frank Zamboni in 1949 in the city of Paramount, California. Frank J. Zamboni & Co, Inc. and other companies manufacture ice resurfacing machines. Zamboni (pronounced /zæmˈboʊni/) is a federally (U.S.) and internationally registered trademark, though the term is often used as a generic colloquialism for ice resurfacing vehicles.

http://www.zamboni.com/

[L-Sami]

Finns det några vetenskaplig artiklar kring ämnet?

[Aimbert]

Ursprungligen postat av L-Sami

Finns det några vetenskaplig artiklar kring ämnet?

Precis.

Jävligt coolt om det visar sig hjälpa i större skala. Varför har man inte hört något om det här?

[bollio]

Ursprungligen postat av Aimbert

Precis.

Jävligt coolt om det visar sig hjälpa i större skala. Varför har man inte hört något om det här?

Det är väl så pass nytt och fräscht att det inte har hunnit hända så mycket. Sjukvården är väl inte så himla snabb heller med att ta till sig ny kunskap.

Tyvärr finns det ju heller inget ekonomiskt motiv (läs: läkemedelsindustrin tjänar inget på detta) för någon att finansiera en sådan studie, så kan ta ett tag.

[mikaelj]

A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.

2009: Zamboni Paolo; Galeotti Roberto; Menegatti Erica; Malagoni Anna Maria; Gianesini Sergio; Bartolomei Ilaria; Mascoli Francesco; Salvi Fabrizio

OBJECTIVE: Chronic cerebrospinal venous insufficiency (CCSVI) is characterized by combined stenoses of the principal pathways of extracranial venous drainage, including the internal jugular veins (IJVs) and the azygous (AZY) vein, with development of collateral circles and insufficient drainage shown by increased mean transit time in cerebral magnetic resonance (MR) perfusion studies. CCSVI is strongly associated with multiple sclerosis (MS). This study evaluated the safety of CCSVI endovascular treatment and its influence on the clinical outcome of the associated MS. METHODS: Sixty-five consecutive patients with CCSVI, subdivided by MS clinical course into 35 with relapsing remitting (RR), 20 with secondary progressive (SP), and 10 with primary progressive (PP) MS, underwent percutaneous transluminal angioplasty (PTA). Mean follow-up was 18 months. Vascular outcome measures were postoperative complications, venous pressure, and patency rate. Neurologic outcome measures were cognitive and motor function assessment, rate of MS relapse, rate of MR active positive-enhanced gadolinium MS lesions (Gad+), and quality of life (QOL) MS questionnaire. RESULTS: Outpatient endovascular treatment of CCSVI was feasible, with a minor and negligible complication rate. Postoperative venous pressure was significantly lower in the IJVs and AZY (P < .001). The risk of restenosis was higher in the IJVs compared with the AZY (patency rate: IJV, 53%; AZY, 96%; odds ratio, 16; 95% confidence interval, 3.5-72.5; P < .0001). CCSVI endovascular treatment significantly improved MS clinical outcome measures, especially in the RR group: the rate of relapse-free patients changed from 27% to 50% postoperatively (P < .001) and of MR Gad+ lesions from 50% to 12% (P < .0001). The Multiple Sclerosis Functional Composite at 1 year improved significantly in RR patients (P < .008) but not in PP or SP. Physical QOL improved significantly in RR (P < .01) and in PP patients (P < .03), with a positive trend in SP (P < .08). Mental QOL showed significant improvement in RR (P < .003) and in PP (P < .01), but not in SP. CONCLUSIONS: PTA of venous strictures in patients with CCSVI is safe, and especially in patients with RR, the clinical course positively influenced clinical and QOL parameters of the associated MS compared with the preoperative assessment. Restenosis rates are elevated in the IJVs but very promising in the AZY, suggesting the need to improve endovascular techniques in the former. The results of this pilot study warrant a subsequent randomized control study.

Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 2009;50(6):1348-58.e1-3.

http://www.biomedexperts.com/Abstrac..._insufficiency